Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia | Zendy

Jay P. Patel | Zendy; Mithat Gönen | Zendy; María E. Figueroa | Zendy; Hugo F. Fernández | Zendy; Zhuoxin Sun | Zendy; Janis Racevskis | Zendy; Pieter Van Vlierberghe | Zendy; Igor Dolgalev | Zendy; Sabrena Thomas | Zendy; Olga Aminova | Zendy; Kety Huberman | Zendy; Janice Cheng | Zendy; Agnès Viale | Zendy; Nicholas D. Socci | Zendy; Adriana Heguy | Zendy; Athena M. Cherry | Zendy; Gail H. Vance | Zendy; Rodney R. Higgins | Zendy; Rhett P. Ketterling | Zendy; Robert E. Gallagher | Zendy; Mark R. Litzow | Zendy; Marcel R.M. van den Brink | Zendy; Hillard M. Lazarus | Zendy; Jacob M. Rowe | Zendy; Selina M. Luger | Zendy; Adolfo A. Ferrando | Zendy; Elisabeth Paietta | Zendy; Martin S. Tallman | Zendy; Ari Melnick | Zendy; Omar AbdelWahab | Zendy; Ross L. Levine | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

Author(s) -

Jay P. Patel,

Mithat Gönen,

María E. Figueroa,

Hugo F. Fernández,

Zhuoxin Sun,

Janis Racevskis,

Pieter Van Vlierberghe,

Igor Dolgalev,

Sabrena Thomas,

Olga Aminova,

Kety Huberman,

Janice Cheng,

Agnès Viale,

Nicholas D. Socci,

Adriana Heguy,

Athena M. Cherry,

Gail H. Vance,

Rodney R. Higgins,

Rhett P. Ketterling,

Robert E. Gallagher,

Mark R. Litzow,

Marcel R.M. van den Brink,

Hillard M. Lazarus,

Jacob M. Rowe,

Selina M. Luger,

Adolfo A. Ferrando,

Elisabeth Paietta,

Martin S. Tallman,

Ari Melnick,

Omar AbdelWahab,

Ross L. Levine

Publication year - 2012

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1112304

Subject(s) - cebpa , npm1 , medicine , daunorubicin , oncology , myeloid leukemia , idh2 , induction chemotherapy , gemtuzumab ozogamicin , leukemia , idh1 , chemotherapy , mutation , karyotype , biology , genetics , gene , cd34 , cd33 , stem cell , chromosome

Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. The prognostic value of recently identified somatic mutations has not been systematically evaluated in a phase 3 trial of treatment for AML.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research